Journal of Neurology Neurosurgery and Psychiatry

Article	Citations
Characteristics of ischaemic stroke associated with COVID-19	520
Parkinson’s disease: etiopathogenesis and treatment	435
Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials	245
Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management	205
Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke	189
TDP-43 proteinopathies: a new wave of neurodegenerative diseases	160
Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism	141
Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions	116
Psychological impact on women health workers involved in COVID-19 outbreak in Wuhan: a cross-sectional study	112
Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic	109
Migraine and risk of stroke	100
Pattern of cognitive deficits in severe COVID-19	99
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)	95
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3	93
Diagnostic and prognostic value of serum NfL and p-Tau181in frontotemporal lobar degeneration	88
Central nervous system complications associated with immune checkpoint inhibitors	87
The future of neuroprotection in stroke	78
Postinfectious brainstem encephalitis associated with SARS-CoV-2	73
Clinical spectrum of high-titre GAD65 antibodies	71
COVID-19–associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network	68
Occupational therapy consensus recommendations for functional neurological disorder	67
Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management	67
Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer’s disease and mild cognitive impairment: a component network meta-analysis	67
Value of systematic genetic screening of patients with amyotrophic lateral sclerosis	66
Neuralgic amyotrophy: a paradigm shift in diagnosis and treatment	65

Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019–2020	65
Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis	63
Diagnostic and therapeutic aspects of hemiplegic migraine	62
Fluid biomarkers in frontotemporal dementia: past, present and future	61
Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study	61
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy	61
Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank	59
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management	58
Decade of progress in motor functional neurological disorder: continuing the momentum	57
Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	56
Advances in the management of glioblastoma	56
Defining causality in COVID-19 and neurological disorders	56
Anatomy and function of the fornix in the context of its potential as a therapeutic target	55
Cerebral microbleeds: from depiction to interpretation	54
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia	52
Management of functional communication, swallowing, cough and related disorders: consensus recommendations for speech and language therapy	51
Performance validity test failure in clinical populations—a systematic review	51
Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK	50
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances	49
Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key eme	49
Clinical trials in REM sleep behavioural disorder: challenges and opportunities	49
Neurology in the time of COVID-19	48
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders	48
Untargeted metabolomics yields insight into ALS disease mechanisms	48
Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features	47
Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS	47
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis	46
A case of limbic encephalitis associated with asymptomatic COVID-19 infection	46
Systematic review of psychotherapy for adults with functional neurological disorder	46
Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease	46
LGI1 antibody encephalitis: acute treatment comparisons and outcome	43
Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study	43
Retinal imaging in Alzheimer’s disease	43
Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial	42
Wilson’s disease: update on pathogenesis, biomarkers and treatments	40
Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers—a developmental disorder	40
Anxiety and depression symptoms after COVID-19 infection: results from the COVID Symptom Study app	40
Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis	40
Neuroinflammation predicts disease progression in progressive supranuclear palsy	39
NOTCH3 variants are more common than expected in the general population and associated with stroke and vascular dementia: an analysis of 200 000 participants	39
Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases	38
Misdiagnosis of prolonged psychogenic non-epileptic seizures as status epilepticus: epidemiology and associated risks	38
Comparison between deep brain stimulation and magnetic resonance-guided focused ultrasound in the treatment of essential tremor: a systematic review and pooled analysis of functional outcomes	38
Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine	38
Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS	37
Understanding the relationship between cognitive performance and function in daily life after traumatic brain injury	37
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial	37
Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis	36
Effects of TPH2 gene variation and childhood trauma on the clinical and circuit-level phenotype of functional movement disorders	35
Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder	35

A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up	34
Mental health and suicide in former professional soccer players	34
Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease	34
Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients	34
Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study	33
Spectrum of impulse control behaviours in Parkinson’s disease: pathophysiology and management	33
Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study	33
In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer’s disease	33
Multimodal MRI for MRgFUS in essential tremor: post-treatment radiological markers of clinical outcome	33
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register	33
Systematic clinical approach for diagnosing upper limb tremor	32
Genotype-associated cerebellar profiles in ALS: focal cerebellar pathology and cerebro-cerebellar connectivity alterations	32
Responsive neurostimulation of the thalamus improves seizure control in idiopathic generalised epilepsy: initial case series	32
Efficacy of deep brain stimulation for treatment-resistant obsessive-compulsive disorder: systematic review and meta-analysis	31
Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen	31
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis	31
Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion	31
Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation	30
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias	30
Bilateral staged magnetic resonance-guided focused ultrasound thalamotomy for the treatment of essential tremor: a case series study	30
Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies	30
Suggestibility in functional neurological disorder: a meta-analysis	29
Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits	29
Early clinical surrogates for outcome prediction after stroke thrombectomy in daily clinical practice	29
Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome	29
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations	28
Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer’s disease	28
Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition	28
Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson’s disease: a cross-sectional study	28
Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions	27
Neuropathology and emerging biomarkers in corticobasal syndrome	27
Carotid web: an occult mechanism of embolic stroke	27
Clinical features ofNOTCH2NLC-related neuronal intranuclear inclusion disease	27
Impact of mobile stroke units	27
Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA)	27
Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies	27
Ischaemic stroke associated with COVID-19 and racial outcome disparity in North America	27
Differentiating tic electrophysiology from voluntary movement in the human thalamocortical circuit	26
Long-term trajectories of decline in cognition and daily functioning before and after stroke	26
Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia	26
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis	26
Lacunar stroke: mechanisms and therapeutic implications	26
Frailty, lifestyle, genetics and dementia risk	26
Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis	26
Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19)	25
Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration	25
Functional disorders after COVID-19 vaccine fuel vaccination hesitancy	25
Deep brain stimulation of the subthalamic nucleus in obsessive–compulsives disorders: long-term follow-up of an open, prospective, observational cohort	25
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study	25
Neurodegenerative disease risk among former international rugby union players	25
Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension	25
Prognostic predictors relevant to end-of-life palliative care in Parkinson’s disease and related disorders: a systematic review	25
Intracranial arterial stenosis in Caucasian versus Chinese patients with TIA and minor stroke: two contemporaneous cohorts and a systematic review	25
Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design	25
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic	25
IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality	24
Long-term functional decline of spontaneous intracerebral haemorrhage survivors	24
Post-traumatic epilepsy in adults: a nationwide register-based study	24
Defining functional brain networks underlying obsessive–compulsive disorder (OCD) using treatment-induced neuroimaging changes: a systematic review of the literature	24
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study	24
Management of patients with generalised myasthenia gravis and COVID-19: four case reports	24
Computerised patient-specific prediction of the recovery profile of upper limb capacity within stroke services: the next step	24
Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects	24
Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data	24
Quality of life in isolated dystonia: non-motor manifestations matter	24
Pattern of paresis in ALS is consistent with the physiology of the corticomotoneuronal projections to different muscle groups	23
GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance	23
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis	23
Factors associated with time to independent walking recovery post-stroke	23
RFC1-related ataxia is a mimic of early multiple system atrophy	23
Fronto-striatal circuits for cognitive flexibility in far from onset Huntington’s disease: evidence from the Young Adult Study	23
Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS	23
EEG to detect early recovery of consciousness in amantadine-treated acute brain injury patients	23
COVID-19 impact on consecutive neurological patients admitted to the emergency department	23
Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis	23
Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis	23
Comorbidity of long COVID and psychiatric disorders after a hospitalisation for COVID-19: a cross-sectional study	23
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis	23
Immunosuppression for intracranial vasculitis associated with SARS-CoV-2: therapeutic implications for COVID-19 cerebrovascular pathology	23
Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants	23

Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon	22
Systematic evaluation of genetic mutations in ALS: a population-based study	22
Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications	22
Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy	22
Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations	22
Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis	22
Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective	21
Concussion symptomology and recovery in children and adolescents with pre-existing anxiety	21
Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion	21
Diffusion imaging in Huntington’s disease: comprehensive review	21
Sex differences for phenotype in pathologically defined dementia with Lewy bodies	21
Apathy, but not depression, predicts all-cause dementia in cerebral small vessel disease	21
Ischaemic stroke in anticoagulated patients with atrial fibrillation	21
Relationship between intensity and recovery in post-stroke rehabilitation: a retrospective analysis	21
Prevalence of dementia in ischaemic or mixed stroke populations: systematic review and meta-analysis	21
Biomarkers in functional movement disorders: a systematic review	21
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS	20
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes	20
Electrical stimulation for seizure induction during SEEG exploration: a useful predictor of postoperative seizure recurrence?	20
Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis	20
Association of obesity with disease outcome in multiple sclerosis	20
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod	20
Cumulative health deficits, APOE genotype, and risk for later-life mild cognitive impairment and dementia	20
Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection	20
Comparison of efficacy of deep brain stimulation and focused ultrasound in parkinsonian tremor: a systematic review and network meta-analysis	20
Making sense of phantom limb pain	20
Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal	20
In vivo PET imaging of neuroinflammation in familial frontotemporal dementia	20
Distinct latent profiles based on neurobehavioural, physical and psychosocial functioning of former National Football League (NFL) players: an NFL-LONG Study	20
Cognitive reserve in amyotrophic lateral sclerosis (ALS): a population-based longitudinal study	20
Adoption of focused ultrasound thalamotomy for essential tremor: why so much fuss about FUS?	19
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab	19
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19	19
Prevalence, predictors and prognosis of incidental intracranial aneurysms in patients with suspected TIA and minor stroke: a population-based study and systematic review	19
Longitudinal changes of spinal cord grey and white matter following spinal cord injury	19
Epilepsy, an orphan disorder within the neurodevelopmental family	19
Acute ischaemic stroke associated with SARS-CoV-2 infection in North America	19
Eculizumab versus rituximab in generalised myasthenia gravis	19
Self-injurious behaviour in movement disorders: systematic review	18
APOE ɛ4dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction	18
Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs	18
Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary intracerebral haemorrhage: population-based study	18
Circadian rhythm of ischaemic core progression in human stroke	17
What is brain fog?	17
Localised increase in regional cerebral perfusion in patients with visual snow syndrome: a pseudo-continuous arterial spin labelling study	17
Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis	17
Genotype–phenotype correlations in valosin-containing protein disease: a retrospective muticentre study	17
CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD	17
Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer’s disease: an observational clinical study	17
De novo mutations in SOD1 are a cause of ALS	17
Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study	17
Frequency of MOG-IgG in cerebrospinal fluid versus serum	17
Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer’s disease	17
Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes	17
Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis	16
Tissue bridges predict neuropathic pain emergence after spinal cord injury	16
Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study	16
Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis	16
Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study	16
Structural and functional changes in the retina in Parkinson’s disease	16
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab	16
Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD)	16
New classification of autoimmune neuropathies based on target antigens and involved domains of myelinated fibres	16
Location of intracranial aneurysms is the main factor associated with rupture in the ICAN population	16
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis	16
Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants	16
Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders	16
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease	15
Great expectations: virus-mediated gene therapy in neurological disorders	15
Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up	15
Nervous system: subclinical target of SARS-CoV-2 infection	15
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease	15
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study	15
Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort	15
Subjective cognitive complaints at age 70: associations with amyloid and mental health	15
Cognition and behaviour in frontotemporal dementia with and without amyotrophic lateral sclerosis	15
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis	15
Intravenous thrombolysis for acute ischaemic stroke during COVID‐19 pandemic in Wuhan, China: a multicentre, retrospective cohort study	15
Brain imaging abnormalities and outcome after acute ischaemic stroke: the ENCHANTED trial	15
Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors	14
Bridging versus direct endovascular therapy in basilar artery occlusion	14
Neurofilament light chain predicts future dementia risk in cerebral small vessel disease	14
Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome	14
Regional hyperperfusion in cognitively normal APOE ε4 allele carriers in mid-life: analysis of ASL pilot data from the PREVENT-Dementia cohort	14
Cognitive decline and diabetes: a systematic review of the neuropathological correlates accounting for cognition at death	14
Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis	14
Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy	14
CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer’s disease	14
CAIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults: the PREVENT-Dementia study	14
Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme	14
Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder	14
Clinical and neuropsychological profile of patients with dementia and chronic traumatic encephalopathy	14
Expanding the spectrum of VEXAS syndrome: association with acute-onset CIDP	14
Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions	14
Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis	14